Article
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Nov 2010
Ingle James N, Schaid Daniel J, Goss Paul E, Liu Mohan, Mushiroda Taisei, Chapman Judy-Anne W, Kubo Michiaki, Jenkins Gregory D, Batzler Anthony, Shepherd Lois, Pater Joseph, Wang Liewei, Ellis Matthew J, Stearns Vered, Rohrer Daniel C, Goetz Matthew P, Pritchard Kathleen I, Flockhart David A, Nakamura Yusuke, Weinshilboum Richard M
Abstract excerpt
PURPOSE: We performed a case-control genome-wide association study (GWAS) to identify single nucleotide polymorphisms (SNPs) associated with musculoskeletal adverse events (MS-AEs) in women treated with aromatase inhibitors (AIs) for early breast cancer. PATIENTS AND METHODS: A nested case-control design was used to select patients enrolled onto the MA.27 phase III trial comparing anastrozole with exemestane....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.